Sutro Biopharma (STRO)


Market Price (11/20/2026): $8.72 | Market Cap: $144.8 MilSector: Health Care | Industry: Biotechnology

Sutro Biopharma (STRO)


Market Price (11/20/2026): $8.72
Market Cap: $144.8 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -92%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -128%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -255%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -57%, Rev Chg QQuarterly Revenue Change % is -6.1%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -287%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -288%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113%

Key risks
STRO key risks include [1] its dependence on an early-stage pipeline following the discontinuation of its previous lead program and [2] financial pressures highlighted by recent corporate restructuring and workforce reductions.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -92%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73%
2 Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -128%
4 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -115 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -255%
6 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -57%, Rev Chg QQuarterly Revenue Change % is -6.1%
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16%
8 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -287%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -288%
9 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113%
10 Key risks
STRO key risks include [1] its dependence on an early-stage pipeline following the discontinuation of its previous lead program and [2] financial pressures highlighted by recent corporate restructuring and workforce reductions.

STRO in ETFs

Weight = STRO's share of each fund

VTI0.00%
ITOT0.00%
IWM0.00%
IWN0.01%
VTWO0.00%
VHT0.00%
IWO0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/19/2026

Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined without company news as the broader market fell, tugged lower again by Nvidia. Chip and financial stocks also saw declines that day.

Down 74.5% from its Jun 29 high to Nov 18 (S&P 500 down 1.2%)
The stock declined significantly over the period, with its biggest daily drops largely coming without specific company news. The largest falls occurred on October 13, without company news, and on August 12, despite reporting encouraging early clinical activity.

Nov 13: up 2.4% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock rose following the company's report of improved net income and diluted EPS for its third quarter 2026, as losses narrowed year-over-year.

Show more
Prices as of 11/19/2026

Nov 16: down 5.1% in one day (S&P 500 down 1.9%)
The stock declined without company news as the broader market fell, tugged lower again by Nvidia. Chip and financial stocks also saw declines that day.

Down 74.5% from its Jun 29 high to Nov 18 (S&P 500 down 1.2%)
The stock declined significantly over the period, with its biggest daily drops largely coming without specific company news. The largest falls occurred on October 13, without company news, and on August 12, despite reporting encouraging early clinical activity.

Nov 13: up 2.4% the day after its Nov 12 earnings report (S&P 500 down 0.4%)
The stock rose following the company's report of improved net income and diluted EPS for its third quarter 2026, as losses narrowed year-over-year.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -63.9% change in STRO stock from 7/31/2026 to 11/19/2026 was primarily driven by a -54.7% change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611192026Change
Stock Price ($)24.178.72-63.9%
Change Contribution By: 
Total Revenues ($ Mil)10045-54.7%
P/S Multiple3.23.21.0%
Shares Outstanding (Mil)1317-21.1%
Cumulative Contribution-63.9%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/19/2026
ReturnCorrelation
STRO-63.9% 
Market (SPY)-3.9%34.3%
Sector (XLV)9.6%31.3%

Fundamental Drivers

The -76.2% change in STRO stock from 4/30/2026 to 11/19/2026 was primarily driven by a -56.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)430202611192026Change
Stock Price ($)36.628.72-76.2%
Change Contribution By: 
Total Revenues ($ Mil)10245-56.0%
P/S Multiple3.13.24.7%
Shares Outstanding (Mil)917-48.3%
Cumulative Contribution-76.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/19/2026
ReturnCorrelation
STRO-76.2% 
Market (SPY)0.1%27.9%
Sector (XLV)22.6%15.8%

Fundamental Drivers

The -22.1% change in STRO stock from 10/31/2025 to 11/19/2026 was primarily driven by a -56.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511192026Change
Stock Price ($)11.208.72-22.1%
Change Contribution By: 
Total Revenues ($ Mil)10445-56.8%
P/S Multiple0.93.2251.3%
Shares Outstanding (Mil)917-48.7%
Cumulative Contribution-22.1%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/19/2026
ReturnCorrelation
STRO-22.1% 
Market (SPY)6.1%21.7%
Sector (XLV)25.1%17.5%

Fundamental Drivers

The -68.3% change in STRO stock from 10/31/2023 to 11/19/2026 was primarily driven by a -63.6% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311192026Change
Stock Price ($)27.508.72-68.3%
Change Contribution By: 
Total Revenues ($ Mil)5745-20.7%
P/S Multiple2.93.29.9%
Shares Outstanding (Mil)617-63.6%
Cumulative Contribution-68.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/19/2026
ReturnCorrelation
STRO-68.3% 
Market (SPY)77.5%24.0%
Sector (XLV)49.8%24.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
STRO Return-31%-46%-47%-57%-37%-25%-96%
Peers Return29%11%-3%-3%24%27%111%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
STRO Win Rate42%42%33%50%58%45% 
Peers Win Rate62%55%47%48%58%56% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
STRO Max Drawdown-48%-78%-76%-68%-75%-79% 
Peers Max Drawdown-17%-20%-24%-23%-22%-17% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: PFE, JNJ, ABBV, AMGN, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/19/2026 (YTD)

How Low Can It Go

EventSTROS&P 500
2025 US Tariff Shock
  % Loss-71.9%-18.8%
  % Gain to Breakeven256.5%23.1%
  Time to Breakeven308 days79 days
2024 Yen Carry Trade Unwind
  % Loss-13.3%-7.8%
  % Gain to Breakeven15.4%8.5%
  Time to Breakeven6 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-52.8%-9.5%
  % Gain to Breakeven112.1%10.5%
  Time to Breakeven44 days24 days
2020 COVID-19 Crash
  % Loss-45.7%-33.7%
  % Gain to Breakeven84.2%50.9%
  Time to Breakeven171 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-41.2%-19.2%
  % Gain to Breakeven70.0%23.8%
  Time to Breakeven679 days105 days

Compare to PFE, JNJ, ABBV, AMGN, REGN

In The Past

Sutro Biopharma's stock fell -71.9% during the 2025 US Tariff Shock. Such a loss loss requires a 256.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventSTROS&P 500
2025 US Tariff Shock
  % Loss-71.9%-18.8%
  % Gain to Breakeven256.5%23.1%
  Time to Breakeven308 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-52.8%-9.5%
  % Gain to Breakeven112.1%10.5%
  Time to Breakeven44 days24 days
2020 COVID-19 Crash
  % Loss-45.7%-33.7%
  % Gain to Breakeven84.2%50.9%
  Time to Breakeven171 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-41.2%-19.2%
  % Gain to Breakeven70.0%23.8%
  Time to Breakeven679 days105 days

Compare to PFE, JNJ, ABBV, AMGN, REGN

In The Past

Sutro Biopharma's stock fell -71.9% during the 2025 US Tariff Shock. Such a loss loss requires a 256.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Sutro Biopharma (STRO)

Sutro Biopharma, Inc. (STRO) is a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing protein therapeutics. Leveraging its proprietary XpressCF+ platform, which integrates cell-free protein synthesis with site-specific conjugation, Sutro aims to create advanced drugs for challenging diseases. The company's primary focus areas are oncology, targeting various cancers, and autoimmune disorders.

Sutro's main product candidates are Antibody-Drug Conjugates (ADCs) currently in Phase 1 clinical trials. STRO-001 is designed to target CD74 for patients battling multiple myeloma and non-Hodgkin lymphoma. Another key candidate, STRO-002, is directed against folate receptor-alpha, intended for patients with ovarian and endometrial cancers. These ADCs represent the company's internal pipeline for specific patient populations.

Beyond its internal drug development, Sutro Biopharma also strategically partners with larger pharmaceutical companies to expand its reach and validate its technology. It holds collaboration and license agreements with Merck, focusing on cytokine derivatives for cancer and autoimmune conditions, and with Celgene Corporation, for the discovery and development of bispecific antibodies and/or ADCs within the immuno-oncology field. These partnerships broaden Sutro's potential impact across diverse therapeutic areas and patient markets.

AI Analysis | Feedback

Here are 1-3 brief analogies for Sutro Biopharma (STRO):

  • It's like an early-stage Moderna, but focused on creating novel protein therapeutics for cancer and autoimmune disorders using its proprietary cell-free synthesis platform, rather than mRNA.

  • It's like an early-stage Seagen (a pioneer in antibody-drug conjugates), but building its next-generation ADC and protein drug pipeline with its unique cell-free synthesis platform.

  • It's like an innovative biotech company, similar to an early-stage Genentech or Amgen, but leveraging its unique cell-free protein synthesis platform to develop advanced protein-based medicines.

AI Analysis | Feedback

  • STRO-001: An antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
  • STRO-002: An antibody-drug conjugate (ADC) directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

AI Analysis | Feedback

```html

Sutro Biopharma (STRO) sells primarily to other companies. Its major customers, based on collaboration and license agreements, include:

  • Merck (MRK)
  • Celgene Corporation (now part of Bristol Myers Squibb, BMY)
```

AI Analysis | Feedback

null

AI Analysis | Feedback

Jane Chung, R.Ph. Chief Executive Officer

Jane Chung was appointed Chief Executive Officer of Sutro Biopharma in March 2025. She brings over 20 years of leadership experience in the pharmaceutical and biotechnology sectors. Prior to her CEO role, she served as Sutro's President and Chief Operating Officer from December 2023, and as Chief Commercial Officer starting in August 2021. Before joining Sutro, Ms. Chung held several leadership positions at AstraZeneca, including President and General Manager of AstraZeneca Canada, and Vice President of Sales and Marketing of U.S. Immuno-Oncology. Her earlier career included commercial roles at Onyx Pharmaceuticals Inc. and Genentech, Inc. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc.

Greg Chow, M.B.A. Chief Financial Officer

Greg Chow was appointed Chief Financial Officer of Sutro Biopharma effective June 2, 2025. He has over 25 years of experience encompassing corporate finance, capital markets, investment banking, financial accounting, and drug development operations. Mr. Chow's previous roles include Chief Financial Officer and Chief Business Officer at NodThera, Chief Financial Officer at Freenome Holdings, Inc., Chief Financial Officer at Frontier Medicines Corp., and Executive Vice President and Chief Financial Officer at Aptose Biosciences, Inc. He was instrumental in financing efforts at these companies, supporting a Series F funding round for Freenome Holdings, guiding Frontier Medicines through Series B and C financings, and leading Aptose Biosciences' dual listing on Nasdaq and the Toronto Stock Exchange while helping raise over $225 million in capital. Earlier in his career, he spent fourteen years in investment banking, holding leadership positions at Wedbush Securities, RBC Capital Markets, and Wells Fargo Securities.

David Pauling, J.D., M.A. Chief Administrative Officer and General Counsel

David Pauling has served as Chief Administrative Officer and General Counsel of Sutro Biopharma since April 2025. He joined Sutro in 2011 and has held positions of increasing responsibility within the company, including Intellectual Property Counsel, Associate General Counsel, Senior Intellectual Property Counsel, and Executive Director of Legal Affairs. In his current role, he is responsible for all aspects of Sutro's legal operations, including governance, compliance, disclosure, intellectual property, and agreements. Before joining Sutro, Mr. Pauling practiced law at Jones Day and Pennie & Edmonds, LLP. He holds a J.D. from Santa Clara University School of Law, and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Hans-Peter Gerber, Ph.D. Chief Scientific Officer

Hans-Peter Gerber has served as Chief Scientific Officer of Sutro Biopharma since September 2023. He brings over three decades of research and development experience in oncology drug development, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies. Dr. Gerber co-founded Codeable Therapeutics in 2022 and previously served as Chief Scientific Officer and Senior Vice President at 3T Biosciences. He built the R&D organization at Maverick Therapeutics, which was acquired by Takeda in 2021, and also served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021. Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, contributing to numerous IND filings and three Biologics License Applications (BLAs), including Avastin®, Mylotarg®, and Besponsa®. Dr. Gerber has contributed to the development of six of the 15 FDA-approved ADCs. He received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.

Devendra Luhar Senior Vice President, Technical Operations

Devendra Luhar currently serves as Senior Vice President, Technical Operations at Sutro Biopharma. He joined Sutro in 2016 as Senior Director of Manufacturing and was promoted to Executive Director in 2018, and later to Vice President of Manufacturing & Plant Operations in August 2020. Mr. Luhar has over 30 years of experience in biotech operations, covering manufacturing, manufacturing science and technology, engineering, and logistics. At Sutro, he has been instrumental in establishing the company's manufacturing organization and GMP compliant operations, and he is responsible for Sutro's cGMP manufacturing facility. Prior to joining Sutro, he held senior leadership positions at companies such as Boehringer-Ingelheim, Novartis, Genzyme, Arbor Vita Corporation, and Baxter BioScience. Mr. Luhar holds a B.A. in Biology from San Jose State University.

AI Analysis | Feedback

The key risks to Sutro Biopharma's business are primarily associated with the inherent challenges of drug development, intense market competition, and ongoing funding requirements.

  1. Clinical Trial Failure and Regulatory Hurdles: As a clinical-stage biopharmaceutical company, Sutro Biopharma's success is highly dependent on its product candidates proving safe and effective in clinical trials and subsequently gaining regulatory approval. All of Sutro's internal product candidates are currently in early-stage development, with STRO-001 in Phase 1 clinical trials and the company shifting focus to earlier-stage candidates like STRO-004, which is in preclinical development. There is a significant risk that positive preclinical data will not translate into clinical success in humans, and many companies in the biotechnology industry have experienced setbacks in late-stage trials despite promising early results. The process of obtaining regulatory approval is complex, time-consuming, and uncertain, and the failure of any product candidate in trials or to secure approval would materially harm the business. The effective discontinuation of luveltamab tazevibulin (formerly STRO-002) further highlights the significant challenges and high failure rates in drug development.
  2. Intense Competition and Market Position: Sutro Biopharma operates within the highly competitive oncology sector, specifically in the rapidly evolving field of Antibody-Drug Conjugates (ADCs). The market includes numerous established pharmaceutical companies and new entrants developing similar therapies. This crowded landscape makes it challenging for Sutro to differentiate its product candidates, especially given their early stage of development. For example, the folate receptor-alpha (FRα) targeting ADC market, which included Sutro's deprioritized luveltamab (STRO-002), is increasingly competitive with other approved products and those under development. The company's ability to successfully advance its pipeline and secure partnerships is crucial for its long-term prospects in this dynamic environment.
  3. Funding Requirements and Potential Dilution: As a company with no products currently on the market, Sutro Biopharma generates minimal revenue, primarily relying on collaborations, and incurs significant losses due to substantial research and development costs. Advancing its product candidates through various clinical development stages requires considerable financial resources. While the company has secured funding, there is an ongoing need for additional capital, which may be obtained through equity offerings, potentially leading to shareholder dilution. The discontinuation of a late-stage asset, such as luveltamab-T, could also impact investor confidence and make it more challenging to secure future funding or partnerships.

AI Analysis | Feedback

null

AI Analysis | Feedback

Sutro Biopharma (NASDAQ: STRO) develops protein therapeutics for cancer and autoimmune disorders. The addressable markets for its main product candidates are substantial and global.

STRO-001 (Antibody-Drug Conjugate targeting CD74)

  • Multiple Myeloma: The global multiple myeloma market was estimated at $27.75 billion in 2024, with projections to reach approximately $49.89 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.04% from 2025 to 2034. Another source indicates the global market size was valued at $29.24 billion in 2025, and is projected to grow to $49.79 billion by 2034, exhibiting a CAGR of 6.10% during the forecast period. The 7 Major Markets (7MM) for multiple myeloma reached a value of $16.4 billion in 2023 and are projected to reach $38.1 billion by 2034, with an 8% CAGR.
  • Non-Hodgkin Lymphoma (NHL): The global non-Hodgkin lymphoma therapeutics market is valued at $10.99 billion in 2025 and is predicted to increase to approximately $20.94 billion by 2034, expanding at a CAGR of 7.43% from 2025 to 2034. The global non-Hodgkin lymphoma treatment market size was valued at $11.59 billion in 2025 and is projected to reach $19.44 billion by 2034, exhibiting a CAGR of 6.25%.

STRO-002 (Antibody-Drug Conjugate targeting Folate Receptor-Alpha)

  • Ovarian Cancer: The global ovarian cancer market was estimated at $3.83 billion in 2024 and is forecast to grow from $4.08 billion in 2025 to $6.81 billion by 2033, at a CAGR of 6.70%. Another report estimates the global market size at $3.5 billion in 2023, with a projected CAGR of 7.2% from 2024 to 2032, reaching approximately $6.5 billion by 2032. Specifically for ovarian cancer, the market is projected to reach $5.1 billion by 2032.
  • Endometrial Cancers: The 7 Major Markets (7MM) for endometrial cancer reached a value of $21.4 billion in 2024 and are expected to reach $31.2 billion by 2035, exhibiting a growth rate (CAGR) of 3.52% during 2025-2035. The global endometrial cancer market is valued at $19.52 billion in 2024 and is projected to reach a value of $29.44 billion by 2035 at a CAGR of 3.80% between 2025 and 2035. Another source indicates the global endometrial cancer market size is calculated at $31.09 billion in 2025 and is expected to reach around $51.15 billion by 2034, expanding at a CAGR of 5.69% from 2025 to 2034.

AI Analysis | Feedback

Sutro Biopharma (STRO) is expected to drive future revenue growth over the next 2-3 years primarily through a combination of strategic collaborations and the advancement of its proprietary clinical pipeline. Given its status as a clinical-stage biopharmaceutical company, significant product sales within this timeframe are unlikely; instead, revenue will largely be generated from partnership activities and milestone achievements.

The key drivers of future revenue growth for Sutro Biopharma are:

  1. Achievement of Milestones from Existing Strategic Partnerships: Sutro Biopharma has established collaborations, notably with Astellas, that are anticipated to yield milestone payments as partnered candidates progress through development. The Astellas partnership, for instance, has a first candidate expected to enter the clinic in 2026. Additionally, the company's existing agreements with Merck and Bristol-Myers Squibb (formerly Celgene) also present opportunities for milestone payments based on research and development achievements.
  2. Entry into New Collaboration and Licensing Agreements: The company is actively pursuing new partnership opportunities to enhance its competitive position. New collaborations typically involve upfront payments and potential future development and regulatory milestones, which would contribute to revenue growth within the specified timeframe.
  3. Progress of Wholly-Owned Pipeline Candidates Through Clinical Development: While direct product sales from Sutro's wholly-owned pipeline are not expected in the near term, successful advancement of its lead programs through clinical trials can trigger significant milestone payments from existing or future partners. Specifically, STRO-004, a lead oncology candidate, is in Phase 1 with key data expected in mid-2026. Another candidate, STRO-006, an ITGB6-targeting exatecan ADC for lung cancer, is projected to have an Investigational New Drug (IND) submission in 2026. Positive clinical validation of these programs could attract new collaborations or expand existing ones, leading to revenue generation.

AI Analysis | Feedback

Share Issuance

  • In February 2026, Sutro Biopharma priced an underwritten public offering of 7,868,383 shares of common stock at $13.98 per share, expecting to generate approximately $110.0 million in gross proceeds.
  • In December 2025, the company implemented a 1-for-10 reverse stock split.
  • In April 2024, Sutro Biopharma raised $75 million through an underwritten offering of common stock.

Inbound Investments

  • Sutro Biopharma received $75 million in upfront payments and an equity investment from Ipsen in April 2024, for licensing exclusive global rights to STRO-003.
  • Revenue for the year ended December 31, 2024, was $62.0 million, primarily derived from collaborations with Astellas and the Tasly agreement.
  • For the year ended December 31, 2023, the company reported revenues of $153.7 million.

Outbound Investments

  • In 2024, the company realized a gain of $32.1 million from the sale of Vaxcyte common stock.

Capital Expenditures

  • Sutro Biopharma plans to decommission its internal GMP manufacturing facility by year-end 2025, transitioning to an external manufacturing strategy.
  • Cash payments estimated to be between $40 million and $45 million are expected to result from a strategic portfolio review and related restructuring in 2025, which includes the manufacturing facility transition.
  • Proceeds from the February 2026 underwritten offering are intended for general corporate purposes, including funding capital expenditures.

Better Bets vs. Sutro Biopharma (STRO)

Peer Outperformance in Biotechnology

STRO has trailed 67% of its 369 Biotechnology peers over 5Y. Among the peers that beat it is ALNY. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that STRO has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
65%
of 452 industry peers · -4.2% return
3Y
38%
of 400 industry peers · -68.5% return
5Y
33%
of 369 industry peers · -95.0% return
Biotechnology peers with revenue growth within 4pp of STRO's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
STRO Sutro Biopharma 46.4% -0.9x -4.2%-68.5%-95.0% —
ALNY Alnylam Pharmaceuticals 43.6% 7.5x -67.9%-10.6%-18.3% +77pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is STRO's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.1%78.5%200.4% CAH 522% · MCK 393% · COR 200%
Health Care Services 20 29.8%19.4%13.7% RDNT 146% · HIMS 119% · DGX 92%
Managed Health Care 8 54.9%-10.9%-9.1% OSCR 154% · HQY 59% · ELV 1%
Health Care Facilities 26 14.5%11.8%-10.2% THC 240% · NHC 208% · EHC 184%
Health Care Equipment 50 -1.7%2.7%-17.2% GKOS 395% · UFPT 330% · TMDX 313%
Health Care Supplies 11 22.8%-2.2%-40.4% LNTH 256% · HAE 114% · MMSI 22%
Pharmaceuticals 60 -15.9%-1.5%-42.0% LQDA 1229% · KNSA 667% · XERS 632%
Life Sciences Tools & Services 110 -21.8%-26.1%-74.7% AXGN 477% · NTRA 181% · MEDP 179%
Biotechnology ← 370 -35.1%-42.2%-84.4% ELVN 1306% · TRVI 1194% · DNTH 1168%
Health Care Technology 23 -20.5%-61.1%-88.1% VEEV -14% · DOCS -52%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

STROPFEJNJABBVAMGNREGNMedian
NameSutro Bi.Pfizer Johnson .AbbVie Amgen Regenero. 
Mkt Price8.7227.77270.43285.00444.82927.14277.72
Mkt Cap0.1158.3651.6504.2240.694.3199.5
Rev LTM4563,62499,33566,01438,90316,89651,264
Op Inc LTM-11516,62425,52523,74912,6105,13414,617
FCF LTM-13011,78619,59518,8729,5813,62810,684
FCF 3Y Avg-15510,13019,10018,0609,1343,6099,632
CFO LTM-12914,17326,15920,08912,0354,84613,104
CFO 3Y Avg-15312,83825,17019,15310,8064,72111,822

Growth & Margins

STROPFEJNJABBVAMGNREGNMedian
NameSutro Bi.Pfizer Johnson .AbbVie Amgen Regenero. 
Rev Chg LTM-57.3%1.3%7.8%10.7%8.2%18.6%8.0%
Rev Chg 3Y Avg46.4%-2.9%5.9%6.3%13.3%9.1%7.7%
Rev Chg Q-6.1%-0.4%5.9%10.3%8.5%36.3%7.2%
QoQ Delta Rev Chg LTM-1.3%-0.1%1.4%2.5%2.1%8.8%1.8%
Op Inc Chg LTM15.9%-1.7%7.9%65.3%45.4%34.8%25.3%
Op Inc Chg 3Y Avg13.1%16.3%4.4%17.8%18.4%6.9%14.7%
Op Mgn LTM-254.7%26.1%25.7%36.0%32.4%30.4%28.3%
Op Mgn 3Y Avg-154.9%23.3%25.4%29.2%25.2%28.9%25.3%
QoQ Delta Op Mgn LTM33.8%-0.6%-1.1%2.0%2.4%3.5%2.2%
CFO/Rev LTM-287.0%22.3%26.3%30.4%30.9%28.7%27.5%
CFO/Rev 3Y Avg-187.8%20.6%27.1%31.7%29.9%31.6%28.5%
FCF/Rev LTM-287.7%18.5%19.7%28.6%24.6%21.5%20.6%
FCF/Rev 3Y Avg-189.5%16.2%20.6%29.9%25.3%24.2%22.4%

Valuation

STROPFEJNJABBVAMGNREGNMedian
NameSutro Bi.Pfizer Johnson .AbbVie Amgen Regenero. 
Mkt Cap0.1158.3651.6504.2240.694.3199.5
P/S3.22.56.67.66.25.65.9
P/Op Inc-1.39.525.521.219.118.418.7
P/EBIT-1.322.734.831.917.616.420.1
P/E-0.939.240.548.725.619.632.4
P/CFO-1.111.224.925.120.019.519.7
Total Yield-107.4%8.8%4.5%4.5%6.3%5.5%5.0%
Dividend Yield0.0%6.2%2.0%2.4%2.3%0.4%2.1%
FCF Yield 3Y Avg-130.2%6.5%4.0%4.5%5.1%4.8%4.6%
D/E0.10.40.10.20.20.00.1
Net D/E-0.90.30.00.10.2-0.10.1

Returns

STROPFEJNJABBVAMGNREGNMedian
NameSutro Bi.Pfizer Johnson .AbbVie Amgen Regenero. 
1M Rtn-24.4%-6.4%4.3%-1.4%1.3%14.8%-0.0%
3M Rtn-58.8%1.4%1.6%9.5%3.2%12.2%2.4%
6M Rtn-71.5%10.5%18.0%34.6%32.6%44.5%25.3%
12M Rtn-4.2%19.1%36.5%26.0%33.5%32.6%29.3%
3Y Rtn-68.5%12.5%94.9%127.7%82.0%16.7%49.4%
1M Excs Rtn-14.8%-1.2%9.4%4.5%6.0%19.5%5.2%
3M Excs Rtn-55.2%3.8%4.0%11.6%4.7%14.5%4.3%
6M Excs Rtn-71.1%10.9%18.3%35.0%33.0%44.8%25.7%
12M Excs Rtn-14.1%4.2%26.0%13.4%20.6%16.3%14.9%
3Y Excs Rtn-128.2%-50.3%33.7%62.8%14.0%-47.4%-16.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs)1026215468 
Bristol Myers Squibb Company (BMS)    11
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name EMD Serono)    5
Merck Sharp & Dohme Corporation (Merck)    43
Vaxcyte, Inc. (Vaxcyte)    3
Total102621546862


Operating Income by Segment
$ Mil2025202420232022
Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs)-158-238-89-129
Total-158-238-89-129


Net Income by Segment
$ Mil2025202420232022
Focuses on developing site-specific and novel-format Antibody-Drug Conjugates (ADCs)-191-227-107-119
Total-191-227-107-119


Price Behavior

Price Behavior
Market Price$8.72 
Market Cap ($ Bil)0.1 
First Trading Date09/27/2018 
Distance from 52W High-78.7% 
   50 Days200 Days
DMA Price$12.38$22.64
DMA Trenddowndown
Distance from DMA-29.6%-61.5%
 3M1YR
Volatility71.9%86.3%
Downside Capture440.38138.89
Upside Capture86.86126.13
Correlation (S&P 500)39.0%23.9%
STRO Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.611.071.371.381.181.54
Up Beta-17.86-0.082.113.833.171.46
Down Beta-3.10-0.92-0.631.020.301.77
Up Capture-174%-85%-64%-60%52%106%
Bmk +ve Days12182862130427
Stock +ve Days6142150116337
Down Capture558%411%372%213%103%111%
Bmk -ve Days10253664121325
Stock -ve Days16294376133403

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STRO
STRO-2.0%86.3%0.35-
Sector ETF (XLV)18.3%17.1%0.8018.5%
Equity (SPY)9.7%13.9%0.4124.1%
Gold (GLD)-10.5%29.0%-0.3912.6%
Commodities (DBC)28.2%21.5%1.05-4.2%
Real Estate (VNQ)8.8%14.3%0.346.9%
Bitcoin (BTCUSD)-32.3%43.7%-0.7817.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STRO
STRO-46.8%89.9%-0.30-
Sector ETF (XLV)7.7%15.4%0.3026.8%
Equity (SPY)10.5%17.3%0.4425.9%
Gold (GLD)14.0%19.2%0.583.1%
Commodities (DBC)6.8%19.6%0.23-1.9%
Real Estate (VNQ)0.7%19.0%-0.0720.1%
Bitcoin (BTCUSD)-0.6%51.4%0.1716.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with STRO
STRO-24.9%84.9%-0.03-
Sector ETF (XLV)11.5%16.8%0.5631.9%
Equity (SPY)14.5%18.0%0.6833.5%
Gold (GLD)10.7%16.6%0.522.6%
Commodities (DBC)7.2%18.2%0.316.2%
Real Estate (VNQ)5.8%20.7%0.2326.9%
Bitcoin (BTCUSD)56.3%66.3%0.9614.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity2.3 Mil
Short Interest: % Change Since 1015202615.1%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest6.3 days
Basic Shares Quantity16.6 Mil
Short % of Basic Shares13.6%

Earnings Returns History

Updated 11/20/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/20262.4%-9.1% 
8/12/2026-14.9%-12.0%-28.8%
5/14/20261.4%-20.3%-21.4%
3/23/202610.5%13.0%66.6%
11/6/2025-13.4%-1.4%-9.9%
8/7/20250.3%-2.5%22.8%
5/8/2025-9.1%-8.3%-13.7%
3/13/2025-35.2%-36.3%-51.8%
...
SUMMARY STATS   
# Positive161212
# Negative101413
Median Positive3.8%13.8%18.5%
Median Negative-6.0%-8.7%-13.7%
Max Positive27.8%55.7%89.9%
Max Negative-35.2%-36.3%-51.8%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/12/20262.4%-9.1% 
8/12/2026-14.9%-12.0%-28.8%
5/14/20261.4%-20.3%-21.4%
3/23/202610.5%13.0%66.6%
11/6/2025-13.4%-1.4%-9.9%
8/7/20250.3%-2.5%22.8%
5/8/2025-9.1%-8.3%-13.7%
3/13/2025-35.2%-36.3%-51.8%
11/13/2024-12.9%-32.6%-46.5%
8/13/202411.5%48.1%38.2%
5/13/20242.6%10.6%-7.8%
3/25/202427.8%55.7%6.1%
1/8/20240.3%14.6%37.8%
11/13/202314.5%33.8%89.9%
8/10/2023-1.8%-3.0%6.0%
5/15/20234.3%-4.1%-1.6%
3/30/20233.1%2.5%2.2%
11/8/20222.7%2.5%10.2%
8/8/20226.6%14.9%-9.2%
5/9/20226.0%-5.8%-8.2%
2/28/2022-2.9%-11.0%-5.6%
11/10/2021-0.0%-11.9%-31.5%
8/9/2021-0.5%2.3%14.2%
5/7/20214.2%1.7%2.5%
3/18/2021-0.1%-6.1%-16.5%
11/5/20203.5%18.6%62.7%
SUMMARY STATS   
# Positive161212
# Negative101413
Median Positive3.8%13.8%18.5%
Median Negative-6.0%-8.7%-13.7%
Max Positive27.8%55.7%89.9%
Max Negative-35.2%-36.3%-51.8%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/12/202610-Q
03/31/202605/14/202610-Q
12/31/202503/23/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202403/13/202510-K
09/30/202411/13/202410-Q
06/30/202408/13/202410-Q
03/31/202405/13/202410-Q
12/31/202303/25/202410-K
09/30/202311/13/202310-Q
06/30/202308/10/202310-Q
03/31/202305/15/202310-Q
12/31/202203/30/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/12/202610-Q
06/30/202608/12/202610-Q
03/31/202605/14/202610-Q
12/31/202503/23/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202403/13/202510-K
09/30/202411/13/202410-Q
06/30/202408/13/202410-Q
03/31/202405/13/202410-Q
12/31/202303/25/202410-K
09/30/202311/13/202310-Q
06/30/202308/10/202310-Q
03/31/202305/15/202310-Q
12/31/202203/30/202310-K
09/30/202211/08/202210-Q
06/30/202208/08/202210-Q
03/31/202205/09/202210-Q
12/31/202102/28/202210-K
09/30/202111/10/202110-Q
06/30/202108/09/202110-Q
03/31/202105/07/202110-Q
12/31/202003/18/202110-K
09/30/202011/05/202010-Q
06/30/202008/06/202010-Q
03/31/202005/11/202010-Q
12/31/201903/16/202010-K

Insider Activity

Updated 9/22/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gerber, Hans-PeterCHIEF SCIENTIFIC OFFICERDirectBuy101620250.8017,00013,60757,494Form
2Chow, Gregory KCFODirectBuy101620250.8119,75015,99815,998Form
3Chung, JaneChief Executive OfficerDirectBuy101620250.8012,50010,01198,391Form
4Matsui, ConnieDirectBuy101620250.8050,00039,95039,950Form
5Pauling, DavidChief Admin. Ofcr. & GCDirectBuy101620250.8012,5049,99357,332Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Gerber, Hans-PeterCHIEF SCIENTIFIC OFFICERDirectBuy101620250.8017,00013,60757,494Form
2Chow, Gregory KCFODirectBuy101620250.8119,75015,99815,998Form
3Chung, JaneChief Executive OfficerDirectBuy101620250.8012,50010,01198,391Form
4Matsui, ConnieDirectBuy101620250.8050,00039,95039,950Form
5Pauling, DavidChief Admin. Ofcr. & GCDirectBuy101620250.8012,5049,99357,332Form

Investor Activity (13F)

Updated Nov 20, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Samsara Biocapital, LLC$26.5 Mil2.6%22ADD +419.7%13F
Merck & Co., Inc.$6.8 Mil1.9%14Hold13F
Kynam Capital Management, LP$21.7 Mil1.4%36ADD +81.9%13F
BVF Inc/Il$31.2 Mil1.0%41New13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
BVF Inc/Il$31.2 Mil1.0%41New13F
Samsara Biocapital, LLC$26.5 Mil2.6%22ADD +419.7%13F
Kynam Capital Management, LP$21.7 Mil1.4%36ADD +81.9%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
BVF Inc/Il$31.2 Mil1.0%41New13F
Samsara Biocapital, LLC$26.5 Mil2.6%22ADD +419.7%13F
Kynam Capital Management, LP$21.7 Mil1.4%36ADD +81.9%13F
Merck & Co., Inc.$6.8 Mil1.9%14Hold13F
Core Cache Last Updated: 11/19/2026